fibroblasts, and that the thickness of the subepithelial collagen appears to be Background -Bronchial asthma is charlinked to an increase in bronchial reacterised by airway structural changes, insponsiveness and exacerbation of clinical cluding mucosal inflammatory infiltration manifestations. and subepithelial collagen deposition, that (Thorax 1998;53:21-27) may represent the morphological basis for the chronicity of the disease. The relationship between airway wall thickness Keywords: bronchial asthma, growth factors, fibroblast, remodelling of airway wall.
Score=attack score (daily mean of the sum of 8 symptoms); PEF diurnal=diurnal variation in peak expiratory flow; Dmin=minimum dose of methacholine as the indicator for bronchial sensitivity; unit=equal to one minute of 1.0 mg/ml aerosol inhalation of methacholine.
Methods
in the morning and evening using a Personal Best Peak Flowmeter (Health Scan, Cedar  Grove, New Jersey, USA) and recorded results Asthma was defined as a clinical history of on a diary card. The results of PEF measureintermittent chest tightness, wheezing, coughments were expressed as the best measurements ing, or shortness of breath and documented taken and the diurnal variation in PEF was reversible airflow obstruction (20% imexpressed as the mean value of two weeks provement in peak expiratory flow (PEF) or calculated from the highest minus the lowest forced expiratory volume in one second (FEV 1 ), daily value, divided by the mean. Eight sympeither spontaneous or in response to inhaled tom scores were recorded daily on the diary 2 agonists). All patients satisfied the American card: nocturnal wheeze; nocturnal cough; Thoracic Society criteria for asthma. 10 None morning chest tightness; wheezing during the had received inhaled or orally administered day; limitation of activity; and the effect of corticosteroids or any other anti-inflammatory exercise, cold air, and dust on asthma sympdrugs such as sodium cromoglycate or nedo-toms. A scoring system ranging from 0 to 3 cromil sodium in the previous four months. was used with 0=none, 1=mild, 2=moderate, The mean FEV 1 was 70.5% (range 50-93.6%) and 3=severe. The results were expressed as of the predicted values. The clinical details of the daily mean of the sums of the eight scores. all patients are shown in table 1. The duration The number of inhalations of salbutamol of their symptomatic asthma ranged from 1 to (Glaxo, Tokyo, Japan) taken as required were 30 years. Twenty one asthmatic patients (17 recorded on the diary card. The mean initial men) aged 17-48 years (mean 27 years) were symptom scores and 2 usage were calculated recruited from our hospital. Patients used in-for a two week observation period. haled 2 stimulants only when necessary.
After six days patients returned having abCurrent smokers and patients with <50% of stained from inhaling 2 agonists for at least 12 predicted FEV 1 were excluded. Patients showed hours. Spirometric tests were performed and no signs of upper or lower respiratory disease for methacholine inhalation test measurements at least two weeks before entering the study.
were taken according to the method of TakiEight healthy, non-smoking volunteers from shima et al. 11 Briefly, using an "Astograph" (TCK-6000CV, Chest MI Co, Tokyo, Japan) the hospital staff (five men) aged 19-48 years the dose-response curves of respiratory re-(mean 31 years) were used as controls. All sistance were determined. Baseline values were controls had normal airway reactivity and a measured after the inhalation of an isotonic mean FEV 1 of 89.0% (84.3-97.1%) of the saline solution, then increasing concentrations predicted values.
of methacholine hydrochloride in isotonic The study protocol was approved by the saline were inhaled starting at a concentration ethics committee of Toho University School of of 49 g/ml and increasing stepwise to Medicine and written informed consent was 25 000 g/ml. The cumulative dose that was obtained from all subjects.
administered at the point where the reciprocal of the respiratory resistance decreased linearly was the measurement of bronchial sensitivity   (Dmin). After a further six days the patients At the initial visit a full history was obtained. returned to the hospital and fibreoptic bronSkin prick tests to common aeroallergens choscopy was performed. (house dust mite, cat fur, dog fur, and grass pollen) were performed and blood was taken for measurement of total and specific IgE   (Phadebas RAST; Pharmacia, Uppsala, Swe-Premedication with 0.5 mg atropine sulphate i.m. and 15 mg pentazocine was administered den). Asthmatic subjects measured their PEF group.bmj.com on April 4, 2017 -Published by http://thorax.bmj.com/ Downloaded from to subjects. After the throat had been an-anti-human fibroblast, 1:10 for anti-IGF-I, 1:
10 for anti-TGF-1 , and 1:50 for anti-PDGF. aesthetised with 4% lignocaine spray the subjects inhaled 200 g of salbutamol to prevent The sections were rinsed in PBS and then the appropriate biotinylated immunoglobulin G bronchoconstriction. A bronchoscope (BF type 20, Olympus Co, Tokyo, Japan) was inserted was applied for each monoclonal antibody:
goat anti-mouse IgG (Biosource International, through the mouth. The pharynx, trachea and bronchi were anaesthetised with 2% lignocaine. Camarillo, California, USA) at a dilution of 1: 100, goat anti-turkey IgG (Southern Biotech Oxygen at 4 l/min was administered via nasal cannulae throughout the procedure. Biopsy for-Associates Inc, Birmingham, Alabama, USA) at 1:200, and goat anti-rabbit IgG (Southern ceps (FB-15C, Olympus) were used to collect 2-3 biopsy specimens from the spur of a basal Biotech) at 1:400 for 60 minutes. The peroxidase reaction was developed in 3.3′-disegment bronchus of the right lower lobe and from the subcarina of the right upper lobe. aminobenzidine (DAB) 4HCl (2.0 mg/l in Tris buffer) containing 0.03% H 2 O 2 and NaN 3 Inhalation of 200 g salbutamol was administered after the procedure. All subjects (6.5 mg/l). Finally, sections were counterstained with haematoxylin and, after being tolerated the procedure well and there were no instances of bronchoconstriction.
washed in running water, dried with alcohol and treated with xylol. System and specificity controls were included in each staining run using human tonsil obtained from a ton-  Biopsy specimens for light microscopy were sillectomy. Negative controls were performed by substitution of the primary antibodies with mounted in an OCT compound (Miles Scientific, Naperville, Illinois, USA), frozen rap-the same concentration of mouse, turkey or goat non-immune globulin G antibodies. idly in dry ice-acetone, and stored at −70°C. Biopsy specimens for electron microscopy were fixed immediately in 2% glutaraldehyde/1.4% formaldehyde fixative at 4°C for two hours in   After several changes of buffer the tissue was 0.1 M cacodylate buffer at pH 7.2.
post-fixed in 1% osmium tetroxide in cacodylate buffer for 90 minutes at room temperature, dehydrated through ethanol, and   Sections 4 m thick were stained using the finally embedded in epoxy resin. Sections 1 m thick were cut and stained with toluidine blue streptavidin-biotin peroxidase technique (Dako Ltd, High Wycombe, UK). Sections were to determine the orientation of the biopsy by light microscopy. Sections 90 nm thick were treated with 0.3% H 2 O 2 in methanol for 10 minutes to block endogenous peroxidase, and stained with uranyl acetate and lead citrate on 300 mesh copper grids for electron microthen for a further 30 minutes with 2% normal porcine serum to suppress non-specific ab-scopic analysis (JEM-1200EX, Japan Electron, Japan). sorption of immunoglobulins. After rinsing with phosphate buffered saline (PBS) the sections were incubated with the primary monoclonal or polyclonal antibodies overnight at  To avoid observer bias, all microscopic slides 4°C. The following monoclonal antibodies were used: EG1 (Pharmacia) for total eos-and electron micrographs were coded prior to analysis by one observer and read blind. The inophils which recognises the stored form of cationic protein; EG2 (Pharmacia) for ac-thickness of "total" epithelial basement membrane was assessed on two sections stained with tivated eosinophils which recognises the cleaved form of cationic protein; anti-human haematoxylin-eosin and was measured from the base of the bronchial epithelium to the outer fibroblast (Biomeda Corp, Forster, California, USA) for fibroblasts which reacts with the limit of the reticular lamina of the basement membrane at regular intervals of 200 m along subunit of prolyl-4-hydroxylase for identification of fibroblasts 12 13 ; and anti-human the length of each section using an Olympus BHS microscope at a magnification of ×400. insulin like growth factor (IGF)-I (Upstate Biology Inc, Lake Placid, New York, USA) The final result was the mean of all the measurements obtained for each biopsy specimen. which is specific to IGF-I (95%) but has 5% cross reactivity to IGF-3.
14 15 Turkey anti-The thickness of true basement membrane was determined from three consecutive electron human transforming growth factor 1 (TGF-1 ) and goat anti-human platelet derived growth micrographs for each subject at a final magnification of ×20 000. The "true" basement factor (PDGF) were obtained from Collaborative Research Corp (Bedford, Mas-membrane, which refers to the lamina rara and densa, was measured from the base of the sachusetts, USA). Sections were incubated with a turkey antibody raised against a peptide bronchial epithelium to the edge of the lamina densa adjacent to the underlying reticular layer. corresponding to the first 30 amino acids of mature TGF-1 LC (1-30) which was affinity Two measurements were performed for each electron micrograph at regular intervals of purified against TGF-1 .
16 17 Goat anti-human PDGF antibody reacts with all three dimeric 5.0 m and the final result was calculated as the average of all the measurements obtained forms of PDGF and has been shown to be effective on cryostat sections. 18 19 for each subject.
The number of eosinophils and fibroblasts Optimum dilutions of the antibodies were 1:20 for anti-EG1, 1:30 for anti-EG2, 1:10 for was counted in the submucosal area at a depth delineating the area of the section on a Video * Significantly different from value of control subjects (p<0.05).
Micro Meter System (VM-31, Olympus) and using software for area measurements (Analytical Measuring System, Olympus). The results were expressed as the number of positive   Clinical data are expressed as mean (SD). The cells per square millimetre of submucosa.
The Analytical Measuring System was em-results for clinical data were normally distributed and were analysed using a two-sample ployed to quantify the growth factor expression in the tissue. This was carried out on stored Student's t test. The thickness of the basement membrane, the number of positive cells, and images at a total magnification of ×100. The program allowed for correction of uneven il-the percentage of growth factor expression showed a positive skewed distribution. Nonlumination of the field of view and for operatorcontrolled editing of the image. Measurements parametric data are expressed as median values and range. Differences between groups were of the total tissue area of the field were first recorded. The threshold for positive growth analysed using the Mann-Whitney U test.
Spearman's rank correlation coefficient was factor staining was determined and the area of growth factor measured. The percentage used to examine the association of histological parameters with clinical data, pulmonary funcgrowth factor expression of the tissue was then calculated.
tion, and airway sensitivity. Probability values of p <0.05 were accepted as significant. Intraobserver reproducibility was assessed using the coefficient of variation and at least three replicate measurements of morphometric parameters were performed by the same observer. The coefficient of repeatability, as described by Bland and Altman, 20 was used to compare measurements. The mean coefficient variation for repeated measurements was 5% for thickness of basement membrane, 7% for EG1, 8% for EG2, 11% for fibroblasts, and 9-15% for growth factor expression.
Results
Bronchoscopic examination with endobronchial biopsy specimens was performed successfully and was well tolerated in all subjects. Biopsy material for electron microscopy was not adequate to determine the thickening of "true" basement membrane in five asthmatic subjects. The subepithelial layer was significantly thicker in the biopsies taken from the asthmatic subjects compared with the control subjects (p<0.05; table 2). Electron microscopy showed that this difference was due to the underlying reticular layer since the thickness of the "true" basement membrane was similar between asthmatic and control subjects (fig 1) .
Immunostaining for eosinophils and fibroblasts clearly demonstrated that both were present in the bronchial epithelium and submucosa. The numbers of EG1+ and EG2+ eosinophils were significantly higher in the biopsy specimens taken from the asthmatic subjects than in those taken from the control subjects (EG1+, median 52. group Score=attack score (daily mean of the sum of 8 symptoms); PEF diurnal=diurnal variation of peak expiratory flow; Dmin= minimum dose of methacholine as the indicator for bronchial sensitivity.
of thickening of the subepithelial layer, whereas there was a significant positive correlation between attack score and subepithelial thickness in asthmatic subjects (r S =0.58, p<0.001). Moreover, the degree of thickening was sig- (r S =−0.65, p<0.001; table 3).
Discussion
When the basement membrane thickening observed by light microscopy in the bronchial asthmatic subjects was examined by electron microscopy, the true basement membrane was found to be preserved and the lamina reticularis beneath it had increased in thickness. This increase in thickness correlated with the number of fibroblasts in the bronchial mucosa. These results are in agreement with those previously reported 5 6 8 and suggest that fibroblasts are the cells responsible for the characteristic subepithelial fibrosis observed in asthma and that this phenomenon represents a repair mechanism rather than a regeneration process by the epithelium. Thus, subepithelial collagen as well as a marker of long lasting structural changes of the airway wall, probably related to the chronicity of the disease. 4 The increased deposition of extracellular The degree of thickness of the subepithelial layer correlated with the number of fibroblasts matrix at specific sites in the airway wall in asthma suggests possible parallels in mechfor the asthmatic subjects (r S =0.88, p<0.001) but not for the control subjects (r S =0.70, p= anism between asthma and interstitial lung diseases that involve fibrosis. Increased ex-0.06) (fig 2) . Immunostaining of cryostat sections with the anti-human TGF-1 LC (1-30) pression of a number of growth factors, notably TGF- 22 and PDGF, 23 has been observed in detected the presence of the TGF-1 precursor molecule in the bronchial epithelium, the sub-lung fibrosis and may drive the excessive matrix deposition and cell proliferation, respectively, mucosa, and the airway smooth muscle. PDGF was detected in the epithelial cells and the that characterise these diseases. However, the growth factors involved in fibroblast proinflammatory cells in the submucosa. The pattern of IGF-I distribution showed localisation liferation in vivo remain unknown. TGFstimulates fibroblast proliferation, 24 promotes to the epithelial cells, smooth muscle, and extracellular matrix. No significant differences matrix protein synthesis, 25 and increases the expression of receptors for extracellular were observed in the expression of growth factors between asthmatic and control subjects matrix. 26 27 PDGF causes fibroblast chemotaxis, fibroblast proliferation, and promotes fibro-(median TGF-1 18.0% (range 5-48%) versus 16.0% (range 7-33%), PDGF 37.0% (range blast-mediated tissue matrix contraction. 28 IGF-I is a potent mitogen for fibroblasts and 20-60%) versus 32.5% (range 20-45%), IGF-I 15.0% (range 5-31%) versus 8.0% (range smooth muscle cells, 29 and is able to stimulate collagen synthesis. 30 PDGF and IGF-I act as a 3-32%)). The number of fibroblasts correlated with the expression of TGF-1 (r S =0.50, competence factor and a progression factor for fibroblast proliferation, respectively. 31 32 In the p<0.05) (fig 3) but not with that of PDGF or IGF-I.
present study no significant difference in the expression of any of the growth factors (TGFThe duration of the clinical disease, diurnal PEF, and FEV 1 were not related to the degree 1 , PDGF, or IGF-I) was observed between group.bmj.com on April 4, 2017 -Published by http://thorax.bmj.com/ Downloaded from asthmatic and control subjects. A recent study 33 al were receiving inhaled corticosteroid therapy. The results of the present study suggest that showed that both the mRNA and protein levels for TGF-1 were similar in lung tissue among the subepithelial layer thickening plays a role in promoting bronchial responsiveness. Studies individuals with asthma, a group of individuals with COPD, and a control group with normal have shown that, when the walls of the small airways thicken, even a small degree of bronlung function. Furthermore, the number of PDGF positive cells was similar among asth-choconstriction has a considerable effect on airway resistance and plays a role in bronchial matic subjects, patients with COPD, and nonobstructed smokers, and PDGF receptor-ex-responsiveness. 41 Thus, in asthma, suggested infiltration of the airways by inflammatory pression did not appear different between these groups. 19 Taylor et al 34 found no increase in cells, primarily eosinophils, tissue-damaging proteins cause damage and desquamation of alveolar macrophage PDGF-mRNA expression in vivo in asthmatic subjects and sug-the airway epithelium and bronchial hyperresponsiveness. 42 Moreover, when chronic gest that PDGF-production by alveolar macrophages is unlikely to play a central role persistent inflammation continues, fibroblast proliferation (which is likely to be caused by in the pathogenesis of subepithelial fibrosis in asthma. The IGF-I level in bronchoalveolar TGF-1 ) leads to collagen deposition, airway remodelling occurs, and asthma is aggravated. fluid from patients with idiopathic pulmonary fibrosis is similar to that in controls. 35 There In conclusion, we have shown that the thickening of the subepithelial layer in asthma corhave been no reports on IGF-I expression in the bronchial mucosa in asthma.
relates with the number of fibroblasts and the expression of TGF-1 . Further studies are reIn the present study a weak significant correlation was found in asthmatic subjects be-quired to determine the growth factor sources of this excessive deposition of collagen and how tween the number of fibroblasts and the expression of TGF-1 . The cell types involved to eradicate fibroblast activation, which will be an important key to the future treatment of in the synthesis of growth factors were not identified because we did not double stain. The asthma. pattern of TGF-1 expression is similar to that
